The Cranbury, New Jersey-based biopharmaceutical company, Amicus Therapeutics, has been around since 2002. It first made itself public in 2007. In 2008 expanded from its original headquarters to include two. Although the company was doing extremely well even very early on, it did experience a serious setback in 2009 after The Shire, a major partner, ended a multi-year agreement. However, this was a blessing in disguise since it inspired a company revolution that changed it for the better forever. In addition, it was given a big financial boost in 2010 after the Alzheimer’s Drug Discovery Foundation awarded it a grant of $210,300.
Things continued to go very well for Amicus Therapeutics (GoogleFinance). In November 2013 it acquired and absorbed its competitor, Callidus Biopharma. Amicus’ primary focus is on medical treatments of rare and orphan diseases. It also develops enzyme replacement therapies. Although there are other similar organizations that do such things, Amicus Therapeutics is the leader. Amicus has been led since 2005 by CEO John Crowley. He has served as its Chairman of the Board since 2010. Crowley knows about rare diseases on a very personal level.
Two of his own children have the rare Pompe. It was a passion to save his kids that got him into the rare disease drug research and manufacturing business in the first place. Two other incredibly important roles at the company are Chief Scientific Officer, which has been held by David Lockhart since 2010, and Director of Exploratory Biology, which has been held by Brandon Wustman since 2010, as well. They have a number of medicines currently in the works, but the medicine showing the most potential is migalastat. This is a drug designed to combat Fabry disease. But new drugs are still being invented and developed. All signs indicate that Amicus Therapeutics will be elevated even higher in the future of the medical industry.
More about Amicus Therapeutics at https://yourbeautycraze.com/amicus-therapeutics-introduces-galafold-fabry-disease-patients/